Literature DB >> 12493957

Tc-99m MIBI uptake and its relation to the proliferative potential of brain tumors.

Ilknur Ak1, Zafer Gulbas, Faruk Altinel, Erkan Vardareli.   

Abstract

PURPOSE: Many studies have shown that the S-phase fraction is a reflection of the proliferation potential of tumors, and DNA aneuploidy is more common in malignant tumors. In this preliminary study, the authors assessed the Tc-99m MIBI uptake of brain tumors and its relation to tumor grade and DNA content of the tumor cells.
METHODS: Ten patients (eight male, two female; mean age, 53.2 +/- 6.11 years) with untreated brain tumors were included in the study. SPECT imaging was performed 20 minutes after injection of 740 MBq (20 mCi) Tc-99m MIBI. A single detector camera with a low-energy high-resolution collimator was used for image acquisition. A region of interest was drawn in the tumor area under magnetic resonance guidance. A Tc-99m MIBI uptake index was computed as the mean tumor-to-background ratio. Flow cytometric analysis of fresh tumor tissue specimens was performed immediately. The percentages of cells in the G0/G1, S, and G2/M phases were determined for each patient.
RESULTS: DNA aneuploidy was found in 4 (49%) patients, whereas diploidy was found in 6 (60%) patients. There was a significant positive correlation between the Tc-99m MIBI uptake and the percentage of the S-phase fraction of the cell cycle ( = 0.000, r = 0.95). The Tc-99m MIBI index was significantly greater in aneuploid tumors than in diploid tumors ( < 0.01).
CONCLUSIONS: High-grade brain tumors have increased Tc-99m MIBI uptake compared with that of low-grade tumors. Tc-99m MIBI uptake is correlated with the percentage of the S-phase fraction of the cell and the aneuploidy level of the brain tumor. This preliminary report suggests that Tc-99m MIBI imaging may be useful in the evaluation of the biologic characteristics of brain tumors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12493957     DOI: 10.1097/00003072-200301000-00007

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  7 in total

1.  The effect of regadenoson on the integrity of the human blood-brain barrier, a pilot study.

Authors:  Sadhana Jackson; Richard T George; Martin A Lodge; Anna Piotrowski; Richard L Wahl; Sachin K Gujar; Stuart A Grossman
Journal:  J Neurooncol       Date:  2017-03-17       Impact factor: 4.130

2.  Differential findings of tc-99m sestamibi dual-phase parathyroid scintigraphy between benign and malignant parathyroid lesions in patients with primary hyperparathyroidism.

Authors:  Miju Cheon; Joon Young Choi; Jae-Hoon Chung; Ji Young Lee; Sook Kyung Cho; Jang Yoo; Soo Bin Park; Kyung-Han Lee; Byung-Tae Kim
Journal:  Nucl Med Mol Imaging       Date:  2011-08-19

Review 3.  99mTc-MIBI in the evaluation of breast cancer biology.

Authors:  Silvana Del Vecchio; Marco Salvatore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-23       Impact factor: 9.236

4.  Perioperative single photon emission computed tomography in predicting survival of malignant glioma patients.

Authors:  Vytenis Deltuva; Adomas Bunevicius; Nemira Jurkiene; Ilona Kulakiene; Arimantas Tamasauskas
Journal:  Oncol Lett       Date:  2012-07-19       Impact factor: 2.967

5.  Semi-quantitative analysis of 99mTc-sestamibi retention level for preoperative differential diagnosis of parathyroid carcinoma.

Authors:  Min Zhang; Lihao Sun; Weiwei Rui; Rui Guo; Huihui He; Ying Miao; Hongping Meng; Jianmin Liu; Biao Li
Journal:  Quant Imaging Med Surg       Date:  2019-08

6.  SPECT and PET imaging of meningiomas.

Authors:  Varvara Valotassiou; Anastasia Leondi; George Angelidis; Dimitrios Psimadas; Panagiotis Georgoulias
Journal:  ScientificWorldJournal       Date:  2012-05-01

7.  Pituitary incidentalomas detected with technetium-99m MIBI in patients with suspected parathyroid adenoma: preliminary results.

Authors:  Ekaterina Tiktinsky; Tifha Horne; Michael Friger; Svetlana Agranovich; Sophie Lantsberg
Journal:  World J Nucl Med       Date:  2012-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.